USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22

Moderna announces advances across mRNA pipeline

Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients

Mandaviya asserts govt's commitment towards improving access to quality medical education

India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014

GSK’s new data underscore important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response

PM addresses valedictory function of 9th World Ayurveda Congress

Expressed happiness that more than 30 countries of the world have given recognition to Ayurveda as a traditional system of medicine

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

GSK India announces 9% sales growth across General Medicines and Specialty business

The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.